Yield10 Bioscience, Inc.

YTEN

US98585K8541

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 02:31:02 2024-06-13 pm EDT			5-day change	1st Jan Change
1.493 ^USD	+2.99%		-13.17%	-74.00%

May. 20	Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from S&P TMI Index	CI
May. 15	Earnings Flash (YTEN) YIELD10 BIOSCIENCE Posts Q1 Revenue $300,000	MT

Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from S&P TMI Index

May 19, 2024

Latest news about Yield10 Bioscience, Inc.

Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from S&P TMI Index	May. 19	CI
Earnings Flash (YTEN) YIELD10 BIOSCIENCE Posts Q1 Revenue $300,000	May. 15	MT
Yield10 Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Top Midday Decliners	May. 15	MT
Yield10 Bioscience to Delist From Nasdaq; Shares Drop	May. 15	MT
Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from NASDAQ Composite Index	May. 14	CI
Transcript : Yield10 Bioscience, Inc., Q4 2023 Earnings Call, Apr 01, 2024	Apr. 01
Yield10 Bioscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01	CI
Yield10 Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Yield10 Bioscience, Inc. Announces the Plant Biosafety Office of the Canadian Food Inspection Agency Clear Genome-edited E3902 Camelina for Planting in Canada	Mar. 26	CI
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
Top Midday Gainers	Mar. 21	MT
Yield10 Bioscience, Inc. Grants Global License to VISION Bioenergy Oilseeds, LLC for Herbicide Tolerant Camelina Cultivated for Production of Biofuel Feedstock	Feb. 14	CI
North American Morning Briefing : Stock Futures -2-	Feb. 09	DJ
Lake Street Downgrades Yield10 Bioscience to Hold From Buy, Cuts Price Target to $0.50 From $3	Feb. 08	MT
Wall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than Expected	Feb. 08	MT
US Futures Marginally Lower Ahead of Jobless Claims, Wholesale Trade Data	Feb. 08	MT
Yield10 Bioscience, Inc. Provides an Update on Its Omega-3 Camelina Program	Feb. 07	CI
Yield10 Bioscience, Inc. Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil	Jan. 08	CI
Transcript : Yield10 Bioscience, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Yield10 Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Yield10 Bioscience, Inc. Contemplates Bankruptcy.	Nov. 14	CI
Yield10 Bioscience, Inc. and Biomar Group Aim to Grow Fish Oil on Land	23-10-31	CI
Yield10 Bioscience, Inc. Exercises Option to Finalize an Exclusive, Global Commercial License to Advanced Omega-3 Production Technology from Rothamsted Research	23-10-19	CI
Sector Update: Health Care Stocks Softer Late Afternoon	23-10-18	MT

Chart Yield10 Bioscience, Inc.

Duration

Period

More charts

Yield10 Bioscience, Inc. is an agricultural bioscience company that is leveraging advanced genetics to develop the oilseed Camelina sativa (Camelina) as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and PHA bioplastics for use as biodegradable bioplastics. The Company is pursuing Camelina seed oil products for two market opportunities and value chains. The first product is seed oil produced by Camelina, which is genetically engineered to enable production of high levels of the omega-3 fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA). The second product is Camelina seed oil for use as a low-carbon intensity feedstock oil for biofuels, including biodiesel, renewable diesel (RD) and sustainable aviation fuel (SAF).

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Yield10 Bioscience, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.493 USD

Average target price

12 USD

Spread / Average Target

+703.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
YIELD10 BIOSCIENCE, INC.	-74.00%	932K
MODERNA, INC.	+46.03%	56.61B
IQVIA HOLDINGS INC.	-7.53%	39.62B
LONZA GROUP AG	+36.02%	39.25B
CELLTRION, INC.	-9.38%	28.28B
ICON PUBLIC LIMITED COMPANY	+12.31%	26.44B
ALNYLAM PHARMACEUTICALS, INC.	-16.38%	20.12B
UNITED THERAPEUTICS CORPORATION	+30.79%	12.51B
MEDPACE HOLDINGS, INC.	+28.57%	12.48B
BIO-TECHNE CORPORATION	-0.36%	12.2B

Other Biotechnology & Medical Research